CMO Pfizer CentreOne Adds Highly Potent Solid Oral Dose to Portfolio

Mar 16, 2017
By Pharmaceutical Technology Editors
Volume 12, Issue 4

CMO Pfizer CentreOne announced that it has added contract manufacturing services of highly potent solid oral dose medicines to its portfolio. Manufacturing will be carried out at the Pfizer Newbridge, Ireland, facility, which is now part of Pfizer CentreOne’s contract manufacturing network. This site, near Dublin, is approved by regulators, including FDA, EMA, Agência Nacional de Vigilância Sanitária (ANVISA) (Brazil), and Pharmaceuticals and Medical Devices Agency (PDMA) (Japan), to supply pharmaceuticals to more than 100 markets.

The Newbridge site has been manufacturing and packaging highly potent solid oral drugs for human use for many years. In addition to conventional manufacturing processes, the local team has experience with compounds that require complex processes, such as modification of powder and particle properties to create novel drug formulations, or those with enhanced solubility and dissolution properties.

Compounds manufactured by Pfizer CentreOne include: highly active compounds, hormones, immunesuppressants, sensitizers, and controlled drugs. Containment technologies span occupational exposure band (OEB) 1–5 (occupational exposure limit down to 0.01 µg/m3). Specialized technologies include active coating, low-dosage formulations, and modified/extended release.

Source: Pfizer CentreOne

lorem ipsum